BiotechTube

AVT06 (proposed aflibercept biosimilar) + Eylea® (Aflibercept)

Phase 3Completed
0 views this week 0 watching💤 Quiet
Interest: 34/100
34
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Neovascular (Wet) AMD

Conditions

Neovascular (Wet) AMD

Trial Timeline

Jun 28, 2022 → Sep 23, 2024

NCT ID
NCT05155293

About AVT06 (proposed aflibercept biosimilar) + Eylea® (Aflibercept)

AVT06 (proposed aflibercept biosimilar) + Eylea® (Aflibercept) is a phase 3 stage product being developed by Alvotech for Neovascular (Wet) AMD. The current trial status is completed. This product is registered under clinical trial identifier NCT05155293. Target conditions include Neovascular (Wet) AMD.

What happened to similar drugs?

18 of 20 similar drugs in Neovascular (Wet) AMD were approved

Approved (18) Terminated (3) Active (2)
✅ranibizumabNovartisApproved
✅RanibizumabNovartisApproved
✅Intraviteal Ranibizumab 0.5mgNovartisApproved
✅RanibizumabNovartisApproved
✅RanibizumabNovartisApproved
✅RanibizumabNovartisApproved
✅BrolucizumabNovartisApproved

Hype Score Breakdown

Clinical
17
Activity
8
Company
9
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT05155293Phase 3Completed

Competing Products

20 competing products in Neovascular (Wet) AMD

See all competitors
ProductCompanyStageHype Score
CLS-AX + Anti-VEGFClearside BiomedicalPhase 1/2
22
CLS-AX + AfliberceptClearside BiomedicalPhase 2
25
Eylea + ALT-L9AlteogenPhase 1
29
UBX1325 injection 50 μL + EYLEA® (aflibercept) Injection 2 mg (0.05mL)Unity BiotechnologyPhase 2
25
DS-7080a + RanibizumabDaiichi SankyoPhase 1
29
Avacincaptad PegolAstellas PharmaPhase 1
29
Avacincaptad Pegol + Avastin + Lucentis + EyleaAstellas PharmaPhase 2
27
Avacincaptad Pegol + LucentisAstellas PharmaPhase 2
35
KHK4951 + Aflibercept InjectionKyowa KirinPhase 2
39
Surabgene Lomparvovec (ABBV-RGX-314) + Ranibizumab ControlAbbViePhase 3
47
Ranibizumab + Local Steroid + Topical SteroidAbbViePhase 2
39
LucentisNovartisPre-clinical
26
ranibizumabNovartisPhase 3
40
BrolucizumabNovartisPre-clinical
18
ranibizumabNovartisApproved
43
brolucizumab + ranibizumab + afliberceptNovartisPre-clinical
26
BeovuNovartisPre-clinical
26
RanibizumabNovartisPhase 3
40
RanibizumabNovartisApproved
43
Intraviteal Ranibizumab 0.5mgNovartisApproved
43